201 related articles for article (PubMed ID: 10494962)
21. Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs.
Chen Z; Aspelund A; Jin H
Vaccine; 2008 Jan; 26(3):361-71. PubMed ID: 18079027
[TBL] [Abstract][Full Text] [Related]
22. Suitability of MDCK cells grown in a serum-free medium for influenza virus production.
Kessler N; Thomas-Roche G; Gérentes L; Aymard M
Dev Biol Stand; 1999; 98():13-21; discussion 73-4. PubMed ID: 10494956
[TBL] [Abstract][Full Text] [Related]
23. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
[TBL] [Abstract][Full Text] [Related]
24. Production of influenza virus in serum-free mammalian cell cultures.
Merten OW; Manuguerra JC; Hannoun C; van der Werf S
Dev Biol Stand; 1999; 98():23-37; discussion 73-4. PubMed ID: 10494957
[TBL] [Abstract][Full Text] [Related]
25. Development of a Vero cell-derived influenza whole virus vaccine.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
[TBL] [Abstract][Full Text] [Related]
26. Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells.
Frensing T; Seitz C; Heynisch B; Patzina C; Kochs G; Reichl U
Vaccine; 2011 Sep; 29(41):7125-9. PubMed ID: 21651940
[TBL] [Abstract][Full Text] [Related]
27. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
[TBL] [Abstract][Full Text] [Related]
28. Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses.
Opitz L; Salaklang J; Büttner H; Reichl U; Wolff MW
Vaccine; 2007 Jan; 25(5):939-47. PubMed ID: 17011087
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
30. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U
Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619
[TBL] [Abstract][Full Text] [Related]
31. Design and optimization of a multiplex anti-influenza peptide immunoassay.
Drummond JE; Shaw EE; Antonello JM; Green T; Page GJ; Motley CO; Wilson KA; Finnefrock AC; Liang X; Casimiro DR
J Immunol Methods; 2008 May; 334(1-2):11-20. PubMed ID: 18329663
[TBL] [Abstract][Full Text] [Related]
32. Mathematical model of influenza A virus production in large-scale microcarrier culture.
Möhler L; Flockerzi D; Sann H; Reichl U
Biotechnol Bioeng; 2005 Apr; 90(1):46-58. PubMed ID: 15736163
[TBL] [Abstract][Full Text] [Related]
33. The growth of attenuated influenza vaccine donor strains in continuous cell lines.
Audsley JM; Tannock GA
J Virol Methods; 2005 Feb; 123(2):187-93. PubMed ID: 15620401
[TBL] [Abstract][Full Text] [Related]
34. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture.
Genzel Y; Behrendt I; König S; Sann H; Reichl U
Vaccine; 2004 Jun; 22(17-18):2202-8. PubMed ID: 15149778
[TBL] [Abstract][Full Text] [Related]
35. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.
Huber VC; McCullers JA
J Infect Dis; 2006 Mar; 193(5):677-84. PubMed ID: 16453263
[TBL] [Abstract][Full Text] [Related]
36. Cell culture influenza vaccine: an Australian perspective.
Chang L; Crichton R; Nandapalan P
Dev Biol Stand; 1999; 98():177-81; discussion 197. PubMed ID: 10494971
[TBL] [Abstract][Full Text] [Related]
37. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent.
Opitz L; Zimmermann A; Lehmann S; Genzel Y; Lübben H; Reichl U; Wolff MW
J Virol Methods; 2008 Dec; 154(1-2):61-8. PubMed ID: 18840469
[TBL] [Abstract][Full Text] [Related]
38. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
39. [Development of a novel influenza vaccine derived from a continuous cell line].
Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
[TBL] [Abstract][Full Text] [Related]
40. Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines.
van Wielink R; Kant-Eenbergen HC; Harmsen MM; Martens DE; Wijffels RH; Coco-Martin JM
J Virol Methods; 2011 Jan; 171(1):53-60. PubMed ID: 20933017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
